HilleVax, Inc. (NASDAQ:HLVX - Get Free Report)'s share price fell 0.5% during mid-day trading on Monday . The stock traded as low as $2.03 and last traded at $2.05. 85,273 shares traded hands during trading, a decline of 82% from the average session volume of 465,548 shares. The stock had previously closed at $2.06.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "neutral" rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st.
View Our Latest Research Report on HilleVax
HilleVax Trading Down 0.5%
The stock has a market cap of $104.79 million, a PE ratio of -0.97 and a beta of 0.76. The company's 50 day moving average is $1.94 and its 200-day moving average is $1.85.
HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.25. As a group, analysts forecast that HilleVax, Inc. will post -2.64 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new position in HilleVax during the 4th quarter worth $26,000. Callan Family Office LLC bought a new stake in shares of HilleVax during the 1st quarter valued at about $28,000. Federated Hermes Inc. grew its position in shares of HilleVax by 128.3% during the 1st quarter. Federated Hermes Inc. now owns 24,429 shares of the company's stock valued at $35,000 after buying an additional 13,728 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of HilleVax during the 1st quarter valued at about $36,000. Finally, AQR Capital Management LLC grew its position in shares of HilleVax by 38.0% during the 1st quarter. AQR Capital Management LLC now owns 33,495 shares of the company's stock valued at $49,000 after buying an additional 9,228 shares during the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.
About HilleVax
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Read More
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
